-
-
-
-
-
-
-
Lexaria Releases Annual Letter from the CEO
-
-
-
-
-
-
-
Lexaria Bioscience closes $3.5 million registered direct offering
-
-
-
-
-
-
-
Lexaria Bioscience hires advisory firm, receives 4 new patents
-
-
-
-
-
-
-
Lexaria's Technology Supports Higher Levels of the GLP-1 Drug Semaglutide in Brain
-
-
-
-
-
-
-
Lexaria Provides Positive Interim Results on Partial 8-week Data from Phase 1b, GLP-1-H24-4 Study
-
-
-
-
-
-
-
Lexaria's (LEXX) DehydraTECH-Liraglutide Human GLP-1 Clinical Study Supports Pathway to Potential FDA Registration as an Orally-Delivered Capsule
-
-
-
-
-
-
-
Lexaria Announces $2 Million Registered Direct Offering of Common Stock
-
353,174 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

